Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | EVP, Research and Development | February 27, 2024 | February 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date February 27, 2024 · Filed February 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 319,128 |
Reported balance
After 2024-02-27 transaction · row 1
1 source rowRow 1 · 2024-02-27 · Sale · Disposed 4,930 · Balance 319,128 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 92,412 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2027-05-18 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 150,444 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 55,536 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 48,252 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 12,156 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 8,436 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-05 · Disposition to issuer · Disposed 91,584 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-05 · Disposition to issuer · Disposed 13,728 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-05 · Disposition to issuer · Disposed 155,028 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-05 · Disposition to issuer · Disposed 93,024 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-05 · Disposition to issuer · Disposed 47,808 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-05 · Disposition to issuer · Disposed 76,488 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
F5: These stock options were granted with automatic vesting on exercisable date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2024 Filed Feb 29, 2024 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 4,930 | $6.10 | $30,073.00 |
DisclosureSEC source: 0001600620-24-000028 · wk-form4_1709241050.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,128 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:35 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 25,146 | $5.48 | $137,800.08 |
DisclosureSEC source: 0001600620-24-000022 · wk-form4_1708637692.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,058 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs granted on August 1, 2022 grant. F2 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 shares of common stock were acquired on May 31, 2023 and 2,430 shares of common stock were acquired on November 30, 2023. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:28 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 191,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-006527 · wf-form4_167813808294932.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,274 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 191,462 newly awarded RSUs and 152,812 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning August 1, 2023. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 20:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Units · Derivative | 152,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-019950 · wf-form4_165938480733710.xml · derivative · entry 2 Knappertz Volker · CIK 0001754122 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,812 Underlying: Common Shares · 152,812 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning August 1, 2023. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning August 1, 2023. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning August 1, 2023. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 20:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 256,892 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001628280-22-019950 · wf-form4_165938480733710.xml · derivative · entry 1 Knappertz Volker · CIK 0001754122 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,892 Underlying: Common Stock · 256,892 shares Expires 2032-08-01 F1 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 76,488 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 12 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 76,488 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 47,808 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 11 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 47,808 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 93,024 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 10 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 93,024 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 155,028 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 9 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 155,028 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 13,728 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 8 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,728 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 91,584 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 7 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 91,584 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 8,436 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 6 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,436 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 12,156 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 5 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,156 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 48,252 | Not disclosed Strike: $14.33 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 4 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 48,252 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 55,536 | Not disclosed Strike: $9.61 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 3 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 55,536 shares Expires 2028-02-26 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 150,444 | Not disclosed Strike: $8.64 | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · derivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 150,444 shares Expires 2027-05-18 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerOrdinary Shares | 92,412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018663 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 3,060 | $18.10 | $55,386.00 |
DisclosureSEC source: 0000899243-21-014010 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,412 F1 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 6,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · derivative · entry 9 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,864 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 2,712 | $17.85 | $48,409.20 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · nonDerivative · entry 6 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,472 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 6,864 | $0.00 | $9.61 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · nonDerivative · entry 5 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 8,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · derivative · entry 8 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,448 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 112,548 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · derivative · entry 7 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 112,548 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 3,325 | $17.90 | $59,517.50 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · nonDerivative · entry 4 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,320 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 8,448 | $0.00 | $11.83 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · nonDerivative · entry 3 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 44,291 | $17.90 | $792,808.90 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · nonDerivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,197 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 112,548 | $0.00 | $157.57 |
DisclosureSEC source: 0000899243-21-009218 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:57 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 47,808 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008103 · doc4.xml · derivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,808 Underlying: Ordinary Shares · 47,808 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:57 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 76,488 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008103 · doc4.xml · derivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,488 Underlying: Ordinary Shares · 76,488 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 6,000 | $11.67 | $70,020.00 |
DisclosureSEC source: 0000899243-21-002560 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,940 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADSs"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 12,000 | $10.50 | $126,000.00 |
DisclosureSEC source: 0000899243-20-032225 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,940 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADSs"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 6,000 | $10.00 | $60,000.00 |
DisclosureSEC source: 0000899243-20-031062 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,940 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADSs"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 6,000 | $9.17 | $55,020.00 |
DisclosureSEC source: 0000899243-20-030504 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,940 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADSs"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 6,000 | $11.11 | $66,660.00 |
DisclosureSEC source: 0000899243-20-021685 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,940 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADSs"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 6,000 | $11.42 | $68,520.00 |
DisclosureSEC source: 0000899243-20-020102 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,940 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 18,000 | $10.35 | $186,300.00 |
DisclosureSEC source: 0000899243-20-017299 · doc4.xml · nonDerivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,940 F6 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2020. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADSs"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 93,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015690 · doc4.xml · derivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,024 Underlying: Ordinary Shares · 93,024 shares Expires not disclosed F2 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 155,028 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015690 · doc4.xml · derivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,028 Underlying: Ordinary Shares · 155,028 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 12,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013769 · doc4.xml · derivative · entry 6 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,144 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 121,476 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013769 · doc4.xml · derivative · entry 5 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 121,476 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 5,868 | $9.67 | $56,743.56 |
DisclosureSEC source: 0000899243-20-013769 · doc4.xml · nonDerivative · entry 4 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,688 F3 · shares: Represented by ADS. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 12,144 | $0.00 | $14.57 |
DisclosureSEC source: 0000899243-20-013769 · doc4.xml · nonDerivative · entry 3 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 5,868 | $9.67 | $56,743.56 |
DisclosureSEC source: 0000899243-20-013769 · doc4.xml · nonDerivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,412 F3 · shares: Represented by ADS. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 121,476 | $0.00 | $145.77 |
DisclosureSEC source: 0000899243-20-013769 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 3,420 | $8.32 | $28,454.40 |
DisclosureSEC source: 0000899243-20-006993 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,392 F1 · kind: Automatic sale to cover vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 18:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 180 | $9.26 | $1,666.80 |
DisclosureSEC source: 0000899243-20-006329 · doc4.xml · nonDerivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,812 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 18:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 2,832 | $9.17 | $25,969.44 |
DisclosureSEC source: 0000899243-20-006329 · doc4.xml · nonDerivative · entry 1 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,992 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 20, 2019 Filed May 21, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 6,312 | $14.76 | $93,165.12 |
DisclosureSEC source: 0000899243-19-014292 · doc4.xml · nonDerivative · entry 3 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,824 F4 · shares: Represented by ADSs. F6 · price: The price reported in Column 4 is a weighted average price per ordinary share ($177.13 per ADS). These shares were sold in multiple transactions at prices ranging from $177.06 per ADS (or $14.76 per ordinary share) to $177.13 per ADS (or $14.76 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2019 Filed May 21, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 5,832 | $14.52 | $84,680.64 |
DisclosureSEC source: 0000899243-19-014292 · doc4.xml · nonDerivative · entry 2 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,136 F4 · shares: Represented by ADSs. F5 · price: The price reported in Column 4 is price per ordinary share converted from price per ADS. Read SEC document |
| May 18, 2019 Filed May 21, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionRestricted Stock Units · Derivative | 12,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014292 · doc4.xml · derivative · entry 4 Knappertz Volker · CIK 0001754122 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,144 shares Expires 2019-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018. These ordinary shares are subsequently converted into American Depositary Shares ("ADS") of the Issuer. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 17, 2019. F7 · derivative.expiration_date: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 12,144 ordinary shares vesting on May 18, 2019 and expiring on March 15, 2020. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.